The 14 Hemophilia Treatment Centers in Mid-Atlantic Region III report statistics regarding their patient population to the Core Center annually. This information is used for reporting to our federal grant agency, the Maternal and Child Health Bureau and is also used by the Core Center for monitoring, budget apportionments and program planning.
Active patients by age, race and gender
In 2013, HTCs in the Mid-Atlantic Region III reported 3,467 total patients.
- 31 percent are female
- 77 percent are Caucasian
- 12 percent are African-American
- 6 percent are Hispanic
- 2 percent are Asian/Pacific Islander
Active patients by diagnosis
- Hemophilia A or B: 1,999 patients (58 percent).
- Von Willebrand disease: 1,243 patients (36 percent). 75 percent of female patients have von Willebrand disease.
Other factor deficiencies
- 214 patients with a deficiency in factor I, II, V, VII, X, XI or XIII
- These patients represent 6 percent of the patients in the region
- 2,326 comprehensive evaluations were conducted at Mid-Atlantic Region III HTCs in 2013
- 1,126 patients with hemophila (56 percent) are on home therapy
Primary care physicians (PCPs):
- 2,260 patients in Mid-Atlantic Region III had an identified PCP
- 1,956 reports were sent from Mid-Atlantic Region III HTCs to PCPs
- 9 percent increase in patients in the Region from 2012 (3,150) to 2013 (3,467)